Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases

B L Balint1, L Nagy

  • 1Department of Biochemistry and Molecular Biology, Research Center for Molecular Medicine, University of Debrecen, Medical and Health Science Center, Nagyerdei krt. 98., Debrecen, H-4012, Hungary.

Insights

Selective PPAR Modulators (SPPARMs) offer targeted activation of Peroxisome Proliferator Activated Receptors (PPARs), influencing lipid metabolism and energy balance. This approach promises new therapeutic strategies for metabolic diseases.

Area of Science:

  • Molecular Endocrinology
  • Metabolic Regulation
  • Pharmacology

Background:

  • Peroxisome Proliferator Activated Receptors (PPARs) are crucial regulators of lipid metabolism and energy homeostasis.
  • Dysregulation of PPARs is linked to metabolic disorders such as insulin resistance, obesity, and atherosclerosis.
  • Recent advancements in understanding PPAR molecular function have paved the way for novel therapeutic interventions.

Purpose of the Study:

  • To introduce the concept of Selective PPAR Modulators (SPPARMs).
  • To review the supporting literature and current understanding of SPPARM mechanisms.
  • To provide an overview of PPAR-selective ligands, their mechanisms, and biological effects.

Main Methods:

  • Literature review of structural studies and ligand identification for PPARs.
  • Analysis of molecular mechanisms underlying PPAR activation and cofactor binding.
  • Compilation of data on selective PPAR ligands and their therapeutic implications.

Main Results:

  • SPPARMs modulate PPARs distinctively, leading to differential gene expression and biological outcomes.
  • PPAR ligand-binding pockets exhibit unique characteristics influencing receptor conformation and cofactor interactions.
  • The development of SPPARMs represents a significant advancement in targeting metabolic pathways.

Conclusions:

  • SPPARMs offer a promising therapeutic avenue for metabolic diseases by enabling precise control over PPAR activity.
  • Understanding the molecular details of ligand-receptor interactions is key to designing effective SPPARMs.
  • Further research into SPPARMs holds potential for developing innovative treatments for metabolic disorders.

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Regulation of Metabolism01:19

Regulation of Metabolism

Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: